Nockowitz v. Janssen Pharmaceuticals, Inc., et al

Filing 17

Conditional Transfer Order (CTO-1). Signed by MDL Panel on 12/19/16. (Attachments: # 1 Minute Order)(Copies have been distributed pursuant to the NEF - MMM)

Case NV/2:16-cv-02417 Document 10 Filed 12/19/16 Page 1 of 3

UNITED STATES JUDICIAL PANEL
on
MULTIDISTRICT LITIGATION

IN RE: INVOKANA (CANAGLIFLOZIN)
PRODUCTS LIABILITY LITIGATION

MDL No. 2750

(SEE ATTACHED SCHEDULE)

CONDITIONAL TRANSFER ORDER (CTO −1)

On December 7, 2016, the Panel transferred 18 civil action(s) to the United States District Court for
the District of New Jersey for coordinated or consolidated pretrial proceedings pursuant to 28 U.S.C.
§ 1407. See _F.Supp.3d_ (J.P.M.L. 2016). Since that time, no additional action(s) have been
transferred to the District of New Jersey. With the consent of that court, all such actions have been
assigned to the Honorable Brian R. Martinotti.
It appears that the action(s) on this conditional transfer order involve questions of fact that are
common to the actions previously transferred to the District of New Jersey and assigned to Judge
Martinotti.
Pursuant to Rule 7.1 of the Rules of Procedure of the United States Judicial Panel on Multidistrict
Litigation, the action(s) on the attached schedule are transferred under 28 U.S.C. § 1407 to the
District of New Jersey for the reasons stated in the order of December 7, 2016, and, with the consent
of that court, assigned to the Honorable Brian R. Martinotti.
This order does not become effective until it is filed in the Office of the Clerk of the United States
District Court for the District of New Jersey. The transmittal of this order to said Clerk shall be
stayed 7 days from the entry thereof. If any party files a notice of opposition with the Clerk of the
Panel within this 7−day period, the stay will be continued until further order of the Panel.

Dec 19, 2016

FOR THE PANEL:

Jeffery N. Lüthi
Clerk of the Panel

Case NV/2:16-cv-02417 Document 10 Filed 12/19/16 Page 2 of 3

IN RE: INVOKANA (CANAGLIFLOZIN)
PRODUCTS LIABILITY LITIGATION

MDL No. 2750

SCHEDULE CTO−1 − TAG−ALONG ACTIONS

DIST

DIV.

C.A.NO.

CASE CAPTION

CALIFORNIA CENTRAL
CAC

5

16−02020

Lois Mercado v. Janssen Research and Development,
LLC et al

16−00281

KAMPE v. JANSSEN PHARMACEUTICALS INC

16−01406

Cape v. Janssen Ortho LLC et al

16−09441

Faedtke v. Janssen Pharmaceuticals, Inc.

16−01140

Klein v. Janssen Pharmaceuticals, Inc.

16−00065

Moore et al v. Janssen Research & Development, LLC
et al

16−00658

Tindle v. Janssen Pharmaceuticals, Inc. et al

16−16678

Vetter v. Janssen Pharmaceuticals, Inc. et al

16−01707

Grubbs−Williams et al v. Janssen Pharmaceuticals, Inc.
et al Opposed 12/19/16

FLORIDA NORTHERN
FLN

5

ILLINOIS CENTRAL
ILC

1

ILLINOIS NORTHERN
ILN

1

ILLINOIS SOUTHERN
ILS

3

KENTUCKY EASTERN
KYE

0

KENTUCKY WESTERN
KYW

3

LOUISIANA EASTERN
LAE

2

MISSOURI EASTERN
MOE

4

Case NV/2:16-cv-02417 Document 10 Filed 12/19/16 Page 3 of 3
MOE

4

16−01766

Seamon v. Janssen Pharmaceuticals, Inc. et al

2

16−02417

Nockowitz v. Janssen Pharmaceuticals, Inc., et al

16−02476

Carlson et al v. Janssen Pharmaceuticals, Inc.

16−00407

Ryan v. Janssen Pharmaceuticals, Inc. et al

16−03052
16−03053

Adams v. Janssen Pharmaceuticals, Inc.
Price v. Janssen Pharmaceuticals, Inc.

NEVADA
NV

OHIO NORTHERN
OHN

1

TENNESSEE EASTERN
TNE

1

TENNESSEE MIDDLE
TNM
TNM

3
3